Jim Simons Galectin Therapeutics Inc Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.74 $207,438 - $303,313	-174,318 Reduced 86.29%	27,700 $36,000
Q1 2022 May 13, 2022	SELL	$1.61 - $2.31 $21,545 - $30,912	-13,382 Reduced 6.21%	202,018 $325,000
Q4 2021 Feb 11, 2022	BUY	$2.07 - $3.8 $424,979 - $780,155	205,304 Added 2033.52%	215,400 $446,000
Q3 2021 Nov 12, 2021	SELL	$2.59 - $4.15 $932,666 - $1.49 Million	-360,103 Reduced 97.27%	10,096 $39,000
Q2 2021 Aug 13, 2021	BUY	$2.07 - $5.1 $130,821 - $322,314	63,199 Added 20.59%	370,199 $1.19 Million
Q1 2021 May 13, 2021	BUY	$1.96 - $2.57 $571,091 - $748,828	291,373 Added 1864.55%	307,000 $666,000
Q4 2020 Feb 10, 2021	BUY	$2.24 - $2.87 $35,004 - $44,849	15,627 New	15,627 $35,000
Q2 2020 Aug 13, 2020	SELL	$1.66 - $3.15 $33,366 - $63,315	-20,100 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$1.51 - $3.0 $28,690 - $57,000	-19,000 Reduced 48.59%	20,100 $39,000
Q4 2019 Feb 13, 2020	BUY	$2.79 - $4.32 $109,089 - $168,912	39,100 New	39,100 $112,000
Q3 2019 Nov 13, 2019	SELL	$3.0 - $4.05 $104,196 - $140,664	-34,732 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$3.61 - $5.0 $125,382 - $173,660	34,732 New	34,732 $144,000

112

9.93M

3.78M

5.27M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $87.4M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.